Interrogating open issues in cancer precision medicine with patient-derived xenografts

Annette T. Byrne, Denis G. Alférez, Frédéric Amant, Daniela Annibali, Joaquín Arribas, Andrew V. Biankin, Alejandra Bruna, Eva Budinská, Carlos Caldas, David K. Chang, Robert B. Clarke, Hans Clevers, George Coukos, Virginie Dangles-Marie, S Gail Eckhardt, Eva Gonzalez-Suarez, Els Hermans, Manuel Hidalgo, Monika A. Jarzabek, Steven De JongJos Jonkers, Kristel Kemper, Luisa Lanfrancone, Gunhild Mari Mælandsmo, Elisabetta Marangoni, Jean Christophe Marine, Enzo Medico, Jens Henrik Norum, Héctor G. Palmer, Daniel S. Peeper, Pier Giuseppe Pelicci, Alejandro Piris-Gimenez, Sergio Roman-Roman, Oscar M. Rueda, Joan Seoane, Violeta Serra, Laura Soucek, Dominique Vanhecke, Alberto Villanueva, Emilie Vinolo, Andrea Bertotti, Livio Trusolino

Research output: Contribution to journalReview article

157 Citations (Scopus)

Abstract

Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective of EurOPDX, an international initiative devoted to PDX-based research.

Original languageEnglish (US)
Pages (from-to)254-268
Number of pages15
JournalNature Reviews Cancer
Volume17
Issue number4
DOIs
StatePublished - Apr 1 2017

Fingerprint

Precision Medicine
Heterografts
Neoplasms
Internationality
Therapeutics
Biomarkers
Medicine
Clinical Trials
Pressure

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Byrne, A. T., Alférez, D. G., Amant, F., Annibali, D., Arribas, J., Biankin, A. V., ... Trusolino, L. (2017). Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nature Reviews Cancer, 17(4), 254-268. https://doi.org/10.1038/nrc.2016.140

Interrogating open issues in cancer precision medicine with patient-derived xenografts. / Byrne, Annette T.; Alférez, Denis G.; Amant, Frédéric; Annibali, Daniela; Arribas, Joaquín; Biankin, Andrew V.; Bruna, Alejandra; Budinská, Eva; Caldas, Carlos; Chang, David K.; Clarke, Robert B.; Clevers, Hans; Coukos, George; Dangles-Marie, Virginie; Eckhardt, S Gail; Gonzalez-Suarez, Eva; Hermans, Els; Hidalgo, Manuel; Jarzabek, Monika A.; De Jong, Steven; Jonkers, Jos; Kemper, Kristel; Lanfrancone, Luisa; Mælandsmo, Gunhild Mari; Marangoni, Elisabetta; Marine, Jean Christophe; Medico, Enzo; Norum, Jens Henrik; Palmer, Héctor G.; Peeper, Daniel S.; Pelicci, Pier Giuseppe; Piris-Gimenez, Alejandro; Roman-Roman, Sergio; Rueda, Oscar M.; Seoane, Joan; Serra, Violeta; Soucek, Laura; Vanhecke, Dominique; Villanueva, Alberto; Vinolo, Emilie; Bertotti, Andrea; Trusolino, Livio.

In: Nature Reviews Cancer, Vol. 17, No. 4, 01.04.2017, p. 254-268.

Research output: Contribution to journalReview article

Byrne, AT, Alférez, DG, Amant, F, Annibali, D, Arribas, J, Biankin, AV, Bruna, A, Budinská, E, Caldas, C, Chang, DK, Clarke, RB, Clevers, H, Coukos, G, Dangles-Marie, V, Eckhardt, SG, Gonzalez-Suarez, E, Hermans, E, Hidalgo, M, Jarzabek, MA, De Jong, S, Jonkers, J, Kemper, K, Lanfrancone, L, Mælandsmo, GM, Marangoni, E, Marine, JC, Medico, E, Norum, JH, Palmer, HG, Peeper, DS, Pelicci, PG, Piris-Gimenez, A, Roman-Roman, S, Rueda, OM, Seoane, J, Serra, V, Soucek, L, Vanhecke, D, Villanueva, A, Vinolo, E, Bertotti, A & Trusolino, L 2017, 'Interrogating open issues in cancer precision medicine with patient-derived xenografts', Nature Reviews Cancer, vol. 17, no. 4, pp. 254-268. https://doi.org/10.1038/nrc.2016.140
Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nature Reviews Cancer. 2017 Apr 1;17(4):254-268. https://doi.org/10.1038/nrc.2016.140
Byrne, Annette T. ; Alférez, Denis G. ; Amant, Frédéric ; Annibali, Daniela ; Arribas, Joaquín ; Biankin, Andrew V. ; Bruna, Alejandra ; Budinská, Eva ; Caldas, Carlos ; Chang, David K. ; Clarke, Robert B. ; Clevers, Hans ; Coukos, George ; Dangles-Marie, Virginie ; Eckhardt, S Gail ; Gonzalez-Suarez, Eva ; Hermans, Els ; Hidalgo, Manuel ; Jarzabek, Monika A. ; De Jong, Steven ; Jonkers, Jos ; Kemper, Kristel ; Lanfrancone, Luisa ; Mælandsmo, Gunhild Mari ; Marangoni, Elisabetta ; Marine, Jean Christophe ; Medico, Enzo ; Norum, Jens Henrik ; Palmer, Héctor G. ; Peeper, Daniel S. ; Pelicci, Pier Giuseppe ; Piris-Gimenez, Alejandro ; Roman-Roman, Sergio ; Rueda, Oscar M. ; Seoane, Joan ; Serra, Violeta ; Soucek, Laura ; Vanhecke, Dominique ; Villanueva, Alberto ; Vinolo, Emilie ; Bertotti, Andrea ; Trusolino, Livio. / Interrogating open issues in cancer precision medicine with patient-derived xenografts. In: Nature Reviews Cancer. 2017 ; Vol. 17, No. 4. pp. 254-268.
@article{0eebd3482ab04341b6549c58673286c0,
title = "Interrogating open issues in cancer precision medicine with patient-derived xenografts",
abstract = "Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective of EurOPDX, an international initiative devoted to PDX-based research.",
author = "Byrne, {Annette T.} and Alf{\'e}rez, {Denis G.} and Fr{\'e}d{\'e}ric Amant and Daniela Annibali and Joaqu{\'i}n Arribas and Biankin, {Andrew V.} and Alejandra Bruna and Eva Budinsk{\'a} and Carlos Caldas and Chang, {David K.} and Clarke, {Robert B.} and Hans Clevers and George Coukos and Virginie Dangles-Marie and Eckhardt, {S Gail} and Eva Gonzalez-Suarez and Els Hermans and Manuel Hidalgo and Jarzabek, {Monika A.} and {De Jong}, Steven and Jos Jonkers and Kristel Kemper and Luisa Lanfrancone and M{\ae}landsmo, {Gunhild Mari} and Elisabetta Marangoni and Marine, {Jean Christophe} and Enzo Medico and Norum, {Jens Henrik} and Palmer, {H{\'e}ctor G.} and Peeper, {Daniel S.} and Pelicci, {Pier Giuseppe} and Alejandro Piris-Gimenez and Sergio Roman-Roman and Rueda, {Oscar M.} and Joan Seoane and Violeta Serra and Laura Soucek and Dominique Vanhecke and Alberto Villanueva and Emilie Vinolo and Andrea Bertotti and Livio Trusolino",
year = "2017",
month = "4",
day = "1",
doi = "10.1038/nrc.2016.140",
language = "English (US)",
volume = "17",
pages = "254--268",
journal = "Nature Reviews Cancer",
issn = "1474-175X",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Interrogating open issues in cancer precision medicine with patient-derived xenografts

AU - Byrne, Annette T.

AU - Alférez, Denis G.

AU - Amant, Frédéric

AU - Annibali, Daniela

AU - Arribas, Joaquín

AU - Biankin, Andrew V.

AU - Bruna, Alejandra

AU - Budinská, Eva

AU - Caldas, Carlos

AU - Chang, David K.

AU - Clarke, Robert B.

AU - Clevers, Hans

AU - Coukos, George

AU - Dangles-Marie, Virginie

AU - Eckhardt, S Gail

AU - Gonzalez-Suarez, Eva

AU - Hermans, Els

AU - Hidalgo, Manuel

AU - Jarzabek, Monika A.

AU - De Jong, Steven

AU - Jonkers, Jos

AU - Kemper, Kristel

AU - Lanfrancone, Luisa

AU - Mælandsmo, Gunhild Mari

AU - Marangoni, Elisabetta

AU - Marine, Jean Christophe

AU - Medico, Enzo

AU - Norum, Jens Henrik

AU - Palmer, Héctor G.

AU - Peeper, Daniel S.

AU - Pelicci, Pier Giuseppe

AU - Piris-Gimenez, Alejandro

AU - Roman-Roman, Sergio

AU - Rueda, Oscar M.

AU - Seoane, Joan

AU - Serra, Violeta

AU - Soucek, Laura

AU - Vanhecke, Dominique

AU - Villanueva, Alberto

AU - Vinolo, Emilie

AU - Bertotti, Andrea

AU - Trusolino, Livio

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective of EurOPDX, an international initiative devoted to PDX-based research.

AB - Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective of EurOPDX, an international initiative devoted to PDX-based research.

UR - http://www.scopus.com/inward/record.url?scp=85009959524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009959524&partnerID=8YFLogxK

U2 - 10.1038/nrc.2016.140

DO - 10.1038/nrc.2016.140

M3 - Review article

C2 - 28104906

AN - SCOPUS:85009959524

VL - 17

SP - 254

EP - 268

JO - Nature Reviews Cancer

JF - Nature Reviews Cancer

SN - 1474-175X

IS - 4

ER -